Musculoskeletal disease likely a risk factor for development of dementias
1. Participants reporting a greater number of chronic pain sites had a higher proportion of developing incident all-cause dementia, AD, ...
Tag: rheumatology
Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa
1. Patients receiving secukinumab every 2-weeks showed superior clinical response rates compared to those receiving placebo. 2. Secukinumab was well-tolerated, ...
Risk of hydroxychloroquine retinopathy increases with longer use and higher dosage
1. In this retrospective cohort study, the incidence of hydroxychloroquine retinopathy was 2.5% at 10 years, increasing to 8.6% at ...
Bimekizumab is effective for active psoriatic arthritis in biologic-naïve adults
1. Significantly more patients in the bimekizumab group reached ACR50 at week 16 compared to the placebo. 2. Fungal infections ...
Low-dose interleukin 2 may be beneficial for primary Sjögren syndrome
1. Among patients with primary Sjögren syndrome, therapy with low-dose interleukin 2 significantly improved outcomes as determined by the European ...
Unsupervised online yoga transiently improves symptoms in patients with knee osteoarthritis
1. Compared to a control group, patients with knee osteoarthritis who engaged in online yoga had improvements in pain and ...
Individuals with autoimmune diseases may have an increased risk for cardiovascular diseases
1. An increased incidence of new cardiovascular disease was seen in individuals with autoimmune disease compared to those without. 2. ...
Litifilimab improves symptom burden for patients with systemic lupus erythematosus
1. Litifilimab was associated with a reduction in the number of swollen and tender joints in systemic lupus erythematosus (SLE) ...
Olokizumab is noninferior to adalimumab for the treatment of rheumatoid arthritis
1. Olokizumab was superior to placebo in improving rheumatoid arthritis (RA) symptoms. 2. Olokizumab was also noninferior to adalimumab in ...
Upadacitinib is safe and effective for treatment of non-radiographic axial spondyloarthritis
1. Significantly more patients in the upadacitinib group achieved ASAS40 response at week 14 compared to the placebo group. 2. ...
